A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
A Phase 3 Randomized, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination With Pomalidomide and Dexamethasone Versus Placebo in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
This PHASE3 trial investigates Relapsed/Refractory Multiple Myeloma and is currently actively recruiting participants. Hangzhou Sumgen Biotech Co., Ltd. leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
4 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
First recorded
Jun 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hangzhou Sumgen Biotech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Beijing, China
- • Guangzhou, China
- • Hangzhou, China
- • Luoyang, China
- • Suzhou, China
- • Taiyuan, China
- • Tianjin, China
- • Wuhan, China
- • Xi’an, China
- • Zhengzhou, China